Biotech Stock Performance Review -- Alder Biopharma, Ardelyx, Bellerophon Therapeutics, and Corbus Pharma

Monday, June 26, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, June 26, 2017 /PRNewswire/ --

If you want a Stock Review on ALDR, ARDX, BLPH or CRBP then come over to and sign up for your free customized report today. Today's research on is centered on the following Biotech companies: Alder Biopharmaceuticals Inc. (NASDAQ: ALDR), Ardelyx Inc. (NASDAQ:
ARDX), Bellerophon Therapeutics Inc. (NASDAQ: BLPH), and Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP). These stocks operate in the Healthcare sector, which, according to a Reuters report, has climbed 17% against a 9% gain for the S&P 500 for 2017, trailing only Technology's 19% rise among major groups. These free stocks reports are currently available on Simply sign up for your complimentary member access at:

Alder Biopharma 

Bothell, Washington headquartered Alder Biopharmaceuticals Inc.'s shares rose 1.55%, finishing last Friday's session at $19.70. A total volume of 1.69 million shares was traded, which was above their three months average volume of 687,750 shares. Over the last month, the stock has advanced 16.57%. The Company's shares are trading above their 50-day moving average by 4.94%. Additionally, shares of Alder Biopharma, which discovers, develops, and commercializes therapeutic antibodies in the US, Australia, and Ireland, have a Relative Strength Index (RSI) of 60.91. Your complete research report on ALDR can be retrieved for free at:


On Friday, shares in Fremont, California headquartered Ardelyx Inc. ended the session 6.00% higher at $5.30. The stock recorded a trading volume of 891,114 shares, which was above its three months average volume of 436,230 shares. The Company's shares are trading below their 50-day moving average by 36.78%. Moreover, shares of Ardelyx, which develops and sells therapeutics for the treatment of cardio renal and gastrointestinal diseases in the US, have an RSI of 39.09. A free report on ARDX is just a click away at:

Bellerophon Therapeutics 

Warren, New Jersey headquartered Bellerophon Therapeutics Inc.'s stock jumped 5.84%, to close the day at $1.45 with a total trading volume of 275,765 shares. The Company's shares have advanced 4.32% in the last one month, 5.07% over the previous three months, and 178.74% since the start of this year. The stock is trading 5.42% and 27.47% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Bellerophon Therapeutics, which focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases, have an RSI of 60.46. Sign up for your complimentary research report on BLPH at:

Corbus Pharma 

Shares in Norwood, Massachusetts-based Corbus Pharmaceuticals Holdings Inc. recorded a trading volume of 5.45 million shares, which was above their three months average volume of 918,730 shares. The stock ended at $6.35, up 6.72% from the last trading session. The Company's shares are trading below their 50-day moving average by 1.34%. Furthermore, shares of Corbus Pharma, which focuses on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases, have an RSI of 52.32.

On June 15th, 2017, Corbus Pharma announced that safety and efficacy data from its previously completed Phase-2 clinical study of anabasum, formerly known as JBT-101, for the treatment of diffuse cutaneous systemic sclerosis was presented at the European League Against Rheumatism Annual Meeting in Madrid, Spain. The presentation included a review of the Phase-2 top-line data previously announced, additional data from the study regarding Patient-Reported Outcomes Measurement Information System (PROMIS)-29, and additional analysis of the previously reported CRISS domains and transcriptome data. Register for free on and download the latest research report on CRBP at:

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store